melanotan 2 dosage: Frequently asked questions

This indicates uneven melanocyte stimulation. Moles and freckles contain clustered melanocytes with higher MC1R density, so they respond more aggressively to MT2 than surrounding skin. Lower your dose immediately and avoid further loading. The darkening is reversible as pigmented keratinocytes shed over 28 days, but continued high-dose MT2 can create permanent hyperpigmentation in these areas. Individuals with numerous moles or freckles should start at the absolute minimum dose (0.25mg every other day) and monitor closely.

Increase your dose to 0.75mg daily and add controlled UV exposure (10–15 minutes per session, 2–3 times weekly). Some individuals with low baseline MC1R expression require higher receptor occupancy to initiate melanogenesis. The absence of pigment change at 0.5mg suggests you're below your personal saturation threshold. Monitor for mole darkening as an early indicator of melanocyte activation even before visible skin pigmentation appears. If no change occurs after an additional 10 days at 0.75mg with UV exposure, you may have a genetic MC1R polymorphism (common in red-haired individuals) that reduces receptor responsiveness to synthetic agonists. MT-2 is unlikely to produce meaningful tanning in this population.

Melanocortin receptor tolerance is well-documented. Continuous agonist exposure downregulates receptor density by 20–35% over 14–21 days. Implement a washout period: discontinue MT-2 for 7–10 days to allow receptor upregulation, then resume at your original effective dose. Cycling protocols (5 days on, 2 days off) prevent tolerance development better than continuous administration. If you require sustained effects without cycling, reduce your dose by 30–40% and accept the lower but consistent receptor occupancy rather than chasing diminishing returns with escalating doses.

Reduce dose to 0.25–0.5mg daily and assess whether satiety persists at the lower range. Melanogenesis is cumulative. Existing pigmentation will fade over 4–8 weeks without continued stimulation, but it won't reverse immediately. Some users maintain appetite effects at doses below the tanning threshold once central melanocortin tone has been established, meaning you may not need the same dose long-term that you required during initiation.

Reduce the next dose to 0.1–0.15mg and hold at that level for 3–4 days before attempting 0.25mg again. Severe nausea (lasting >2 hours or causing vomiting) indicates MC4R overstimulation. The receptor subtype responsible for appetite suppression and nausea. Taking the injection before bed and eating a small carbohydrate-rich snack 30 minutes prior reduces gastric irritation. If nausea persists at 0.1mg, discontinue use. Some individuals are MC4R hypersensitive and cannot tolerate MT-2 at any therapeutic dose.

If you've missed fewer than 3 consecutive maintenance doses (roughly 10–14 days), resume at your previous maintenance dose without re-titration. Beyond 14 days, pigment fading becomes visible and receptor tolerance may partially reset. Restart at 0.25mg for 2–3 days, then return to 0.5mg maintenance. Never double-dose to 'catch up'. Melanogenesis is cumulative over days, not hours, and doubling doses only increases nausea risk without accelerating pigment recovery.

Reduce the dose by 50% immediately and extend the loading phase duration. Nausea from MT2 is mediated by MC4R activation in the brainstem area postrema. It's dose-dependent and typically peaks 60–90 minutes post-injection. Splitting the daily dose into two smaller injections (morning and evening) distributes receptor activation and reduces peak plasma concentration, which often eliminates nausea without sacrificing pigmentation gains. If nausea persists below 0.25mg daily, your MC4R sensitivity is unusually high. Consider abandoning MT2 or using anti-emetics like ondansetron (consult a physician), though this addresses the symptom without solving receptor overstimulation.

Reduce your dose by 50% (from 0.5mg to 0.25mg, or from 0.25mg to 0.125mg) and hold at that level for 7 days before attempting further titration. Nausea peaking within 2–4 hours post-injection indicates MC4R overstimulation. Your baseline receptor sensitivity is higher than average, and the standard starting dose exceeds your saturation threshold. Inject in the evening on an empty stomach and consider taking 1g ginger root extract 30 minutes before dosing. If nausea persists beyond 6 hours or prevents eating, discontinue MT-2 and consult a healthcare provider. Persistent symptoms may indicate an idiosyncratic reaction rather than dose-dependent MC4R activation.

Drop back to 0.25mg for two additional weeks to allow melanocortin receptor adaptation, then re-escalate to 0.5mg using ondansetron pretreatment. If nausea persists despite antiemetic use, Melanotan-2 may not be tolerable for you regardless of erectile benefit. Approximately 10–15% of users discontinue due to persistent nausea that doesn't diminish with repeated dosing. This reflects individual variation in MC4R density and gastric melanocortin receptor sensitivity.

Reduce your dose to 0.5mg and reassess after 48 hours. Nausea without efficacy indicates you've exceeded MC4R saturation and triggered systemic effects (likely MC3R antagonism) without improving receptor binding. Nausea correlates with plasma concentration spikes, not receptor-mediated outcomes. If 0.5mg still produces nausea, switch to an accumulation protocol at 0.25mg daily for 7 days to achieve receptor occupancy without acute plasma peaks. Persistent nausea at all doses suggests individual peptidase sensitivity or reconstitution contamination.

Uneven pigmentation typically results from inconsistent injection timing or inadequate subcutaneous administration technique. MT-2 must be injected into subcutaneous fat (not intramuscular) using a 29–31 gauge insulin syringe at a 45-degree angle. Intramuscular injection causes erratic absorption and patchy melanin deposition. Ensure injections occur at the same time daily (circadian MC1R expression varies by up to 30% between morning and evening). If patchiness develops despite proper technique, add brief UV exposure (10 minutes, 2–3 times weekly) to homogenise melanocyte activation across the skin surface.

You likely have a loss-of-function MC1R variant common in red-haired, extremely pale individuals (Fitzpatrick Type I with RHC phenotype). These variants prevent functional receptor expression, meaning MT2 has no melanocyte target to bind. Increasing the dose won't help. The issue is genetic, not pharmacological. Approximately 1–2% of Caucasians are complete MT2 non-responders. Alternatively, if your peptide source lacks purity certification, degraded or underdosed product could explain the lack of response. Verify peptide quality before concluding genetic non-response.

Your metabolic clearance rate is likely at the upper end of the normal range (half-life closer to 33 minutes than 55 minutes), meaning MT-2 clears your system faster than average. Increase your dose incrementally to 0.75–1mg to extend the effective window, or consider splitting the dose: 0.4mg at T-90 minutes and 0.3mg at T-30 minutes to create overlapping plasma curves. Alternatively, investigate co-administration with mild CYP450 inhibitors (grapefruit juice, for example) to slow peptidase-mediated degradation. Though this introduces additional variables.